Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T in CD19+ B Cell Malignancies
NCT03344705Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM19 Chimeric Antigen Receptor T Cell Injection in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Occurrence of study related adverse events at 2 years. Status: unknown.
02
Drugs
IM19 Chimeric Antigen Receptor T Cell Injection
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03344705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344705.